Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL) A Placebo-controlled, Double-Blind Study

被引:62
作者
Pineros, Yanaika S. Sabogal [1 ,2 ]
Bal, Suzanne M. [1 ,2 ]
van de Pol, Marianne A. [2 ]
Dierdorp, Barbara S. [2 ]
Dekker, Tamara [2 ]
Dijkhuis, Annemiek [2 ]
Brinkman, Paul [1 ]
van der Sluijs, Koen F. [2 ]
Zwinderman, Aeilko H. [3 ]
Majoor, Christof J. [1 ]
Bonta, Peter I. [1 ]
Ravanetti, Lara [1 ,2 ]
Sterk, Peter J. [1 ]
Lutter, Rene [1 ,2 ]
机构
[1] Univ Amsterdam, Amsterdam UMC, Dept Resp Med, Amsterdam, Netherlands
[2] Univ Amsterdam, Amsterdam UMC, Dept Expt Immunol, Amsterdam Infect & Immun Inst, Amsterdam, Netherlands
[3] Univ Amsterdam, Amsterdam UMC, Dept Clin Epidemiol Bioinformat & Biostat, Amsterdam, Netherlands
关键词
loss of asthma control; exacerbation; mepolizumab; rhinovirus; 16; challenge; EXHALED NITRIC-OXIDE; MAST-CELL; EOSINOPHILS; EXACERBATIONS; MEPOLIZUMAB; ACTIVATION; EXPRESSION; PHENOTYPES; RECEPTORS; IL-5;
D O I
10.1164/rccm.201803-0461OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: Eosinophils drive pathophysiology in stable and exacerbating eosinophilic asthma, and therefore treatment is focused on the reduction of eosinophil numbers. Mepolizumab, a humanized monoclonal antibody that neutralizes IL-5 and efficiently attenuates eosinophils, proved clinically effective in severe eosinophilic asthma but not in mild asthma. Objectives: To study the effect of mepolizumab on virus-induced immune responses in mild asthma. Methods: Patients with mild asthma, steroid-naive and randomized for eosinophil numbers, received 750 mg mepolizumab intravenously in a placebo-controlled double-blind trial, 2 weeks after which patients were challenged with rhinovirus (RV) 16. FEV1, FVC, fractional exhaled nitric oxide, symptom scores (asthma control score), viral load (PCR), eosinophil numbers, humoral (luminex, ELISA), and cellular (flow cytometry) immune parameters in blood, BAL fluid, and sputum, before and after mepolizumab and RV16, were assessed. Measurements and Main Results: Mepolizumab attenuated baseline blood eosinophils and their activation, attenuated trendwise sputum eosinophils, and enhanced circulating natural killer cells. Mepolizumab did not affect FEV1, FVC, and fractional exhaled nitric oxide, neither at baseline nor after RV16. On RV16 challenge mepolizumab did not prevent eosinophil activation but did enhance local B lymphocytes and macrophages and reduce neutrophils and their activation. Mepolizumab also enhanced secretory IgA and reduced tryptase in BAL fluid. Finally, mepolizumab affected particularly RV16-induced macrophage inflammatory protein-3a, vascular endothelial growth factor-A, and IL-1RA production in BAL fluid. Conclusions: Mepolizumab failed to prevent activation of remaining eosinophils and changed RV16-induced immune responses in mild asthma. Although these latter effects likely are caused by attenuated eosinophil numbers, we cannot exclude a role for basophils.
引用
收藏
页码:508 / 517
页数:10
相关论文
共 38 条
  • [1] The role of the mast cell in the pathophysiology of asthma
    Bradding, P
    Walls, AF
    Holgate, ST
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (06) : 1277 - 1284
  • [2] Secretory IgA: designed for anti-microbial defense
    Brandtzaeg, Per
    [J]. FRONTIERS IN IMMUNOLOGY, 2013, 4
  • [3] Chemokines and the arrest of lymphocytes rolling under flow conditions
    Campbell, JJ
    Hedrick, J
    Zlotnik, A
    Siani, MA
    Thompson, DA
    Butcher, EC
    [J]. SCIENCE, 1998, 279 (5349) : 381 - 384
  • [4] Human mast cells express receptors for IL-3, IL-5 and GM-CSF;: a partial map of receptors on human mast cells cultured in vitro
    Dahl, C
    Hoffmann, HJ
    Saito, H
    Schiotz, PO
    [J]. ALLERGY, 2004, 59 (10) : 1087 - 1096
  • [5] Regulation of IL-5 and IL-5 receptor expression in the bone marrow of allergic asthmatics
    Denburg, JA
    Sehmi, R
    Upham, J
    Wood, L
    Gauvreau, G
    O'Byrne, P
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1999, 118 (2-4) : 101 - 103
  • [6] Identification and Quantification of Basophils in the Airways of Asthmatics Following Segmental Allergen Challenge
    Dijkstra, Dorothea
    Hennig, Christian
    Hansen, Gesine
    Biller, Heike
    Krug, Norbert
    Hohlfeld, Jens M.
    [J]. CYTOMETRY PART A, 2014, 85A (07) : 580 - 587
  • [7] Human and Mouse Eosinophils Have Antiviral Activity against Parainfluenza Virus
    Drake, Matthew G.
    Bivins-Smith, Elizabeth R.
    Proskocil, Becky J.
    Nie, Zhenying
    Scott, Gregory D.
    Lee, James J.
    Lee, Nancy A.
    Fryer, Allison D.
    Jacoby, David B.
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2016, 55 (03) : 387 - 394
  • [8] The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review
    Eng, Stephanie S.
    DeFelice, Magee L.
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2016, 50 (02) : 140 - 158
  • [9] Action of intracellular IL-1 Ra (Type 1) is independent of the IL-1 intracellular signalling pathway
    Evans, I
    Dower, SK
    Francis, SE
    Crossman, DC
    Wilson, HL
    [J]. CYTOKINE, 2006, 33 (05) : 274 - 280
  • [10] Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care
    Fajt, Merritt L.
    Wenzel, Sally E.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : 299 - 311